Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes-Reference-Cited by-同舟云学术

Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes

Published:2020-02-27 Issue:4 Volume:128 Page:298-307
ISSN:0903-4641
Container-title:APMIS
language:en
Short-container-title:APMIS

Author:

Kruger Dinja T.¹²,Opdam Mark²,Sanders Joyce³,Noort Vincent⁴,Boven Epie¹,Linn Sabine C.²⁵⁶

Affiliation:

1. Department of Medical Oncology Amsterdam UMC Vrije Universiteit Amsterdam/Cancer Center Amsterdam Amsterdam The Netherlands

2. Division of Molecular Pathology The Netherlands Cancer Institute Amsterdam The Netherlands

3. Department of Pathology The Netherlands Cancer Institute Amsterdam The Netherlands

4. Division of Biometrics The Netherlands Cancer Institute Amsterdam The Netherlands

5. Department of Medical Oncology The Netherlands Cancer Institute Amsterdam The Netherlands

6. Department of Pathology University Medical Centre Utrecht Utrecht University Utrecht The Netherlands

Funder

Top Institute Pharma

Publisher

Wiley

Subject

Microbiology (medical),General Medicine,Immunology and Allergy,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apm.13026

Reference44 articles.

1. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

2. Comprehensive molecular portraits of human breast tumours

3. Targeted Pathways in Breast Cancer: Molecular and Protein Markers Guiding Therapeutic Decisions

4. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways;Hosford SR;Pharmacogenomics Pers Med,2014

5. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer;ESMO Open;2024-03

2. Synergy between PEDF and Doxorubicin in Breast Cancer Cells: Effects on Metastatic and Metabolic Pathways;International Journal of Molecular Sciences;2024-02-27

3. Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies;Cancer Drug Resistance;2023-11-17

4. Advancing Cancer Therapy Predictions with Patient-Derived Organoid Models of Metastatic Breast Cancer;Cancers;2023-07-13

5. Immunotherapy in Breast Cancer: When, How, and What Challenges?;Biomedicines;2021-11-14